p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1831-1835

  Komiya, Takefumi ^a   Hosono, Yoshimi ^a   Hirashima, Tomonori ^a   Masuda, Noriyuki ^a   Yasumitsu, Tsutomu ^a   Nakagawa, Katsuhiro ^a   Kikui, Masanori ^a   Ohno, Atsuko ^a,b   Fukuoka, Masahiro ^c   Kawase, Ichiro ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PNEUMONECTOMY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030747031     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. (Review). Science (Washington DC), 253: 49-53, 1991.
2. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.
3. Chiba, I., Takahashi, T., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., Reissmann, P., Slamon, D., Holmes, E ., and Minna, J. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer: Lung Cancer Study Group. Oncogene, 5: 1603-1610, 1990.
4. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Takahashi, T., and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52: 734-736, 1992.
5. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
6. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
7. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R., and Takahashi, T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.
8. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85: 2018-2023, 1993.
9. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54: 2496-2503, 1994.
10. Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., and Yamakido, M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res., 85: 1240-1246, 1994.
11. Harpole, D. H., Jr., Herndon, J. E., II, Wolfe, W. G., Igletart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
12. Xu, H. J., Cagle, P. T., Hu, S. X., Li, J., and Benedict, W. F. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin. Cancer Res., 2: 1169-1176, 1996.
13. Fujino, M., Akita, H. D., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in non small cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995.
14. Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., and Hong, W. K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol., 13: 1893-1903, 1995.
15. Morkve, O., Halvorsen, O. J., Skjaerven, R., Stangeland, L., Gulsvik, A., and Laerum, O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res., 13: 571-578, 1993.
16. Passlick, B., Izbicki, J. R., Haussinger, K., Thetter, O., and Pantel, K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 709: 1205-1221, 1995.
17. Ohono, A., Hirashima, T., Kubo, A., Masuda, N., Takada, M., Fujiwara, H., Yasumitsu, T., Kikui, M., Fukuoka, M., and Nakagawa, K. p53 status and prognosis in I-IIa non-small cell lung cancer. Int. J. Oncol., 10: 521-528, 1997.
18. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. Waf1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
19. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
20. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. donation of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell. Res., 211: 90-98, 1994.
21. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
22. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-707, 1993.
23. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
24. Johnson, M., Dimitrov, D., Vojta, P. J., Barrett, J. C., Noda, A., Pereira-Smith, O. M., and Smith, J. R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol. Carcinogenesis, 11: 59-64, 1994.
25. Sheikh, M. S., Li, S. X., Shao, Z. M., Ordonez, J. V., and Fontana, J. A. Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 9: 3407-3414, 1994.
26. El-Deiry, W. S., Tokino, T., Waldman, T., Oilier, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Topological control of p21 WAF1/ CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1994.
27. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo, G., Angeletti, C. A., Palma, P. D., and Bevilacqua, G. p21 RNA, and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12: 1319-1324, 1996.
28. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591-1599, 1996.
29. Mountain, C. F. A new international staging system for lung cancer. Chest (Suppl.), 89: 225s-233s, 1986.
30. Elias, J. M., Margiotta, M., and Gaborc, D. Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and peroxidase-labeled avidin-biotin (LAB) methods. Am. J. Clin. Pathol., 92: 62-67, 1989.
31. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
32. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B., 34: 187-220, 1972.
33. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
34. WAF1/Cip1 in colorectal carcinoma. Br. J. Cancer, 74: 165-171, 1996.
35. Jiang, H., Lin, J., Su, Z. Z., Collart, F. R., Huberman E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
36. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A., and El-Houseini, M. E. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene, 9: 3389-3396, 1994.
37. Marchetti, A., Buttitta, F., Pellegrini, S., Lori, A., Bertacca, G., and Bevi-Lacqua, G. Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at codon 31. Int. J. Oncol., 6: 187-189, 1995.
38. Shiohara, M., El-Diery, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B. V., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
39. Li, Y. J., Laurent-Puig, P., Salmon, R. J., Thomas, G., and Hamelin, R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene, 10: 599-601, 1995.
40. Shimizu, T., Miwa, W, Nakamori, S., Ishikawa, O., Konishi, Y., and Sekiya, T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn. J. Cancer Res., 87: 275-278, 1996.
41. Fan, Z., Lu, Y., Wu, X. P., Deblasio, A., Koff, A., and Mendelsohn, J. Prolonged induction of p21(Cip1/WAF1)CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
42. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor B induces the cyclin-dependent kinases inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
43. Li, C. Y., Suardet, L., and Little, J. B. Potential role of WAF1/ Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
44. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27 kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
45. Lee, M. H., Reynisdottir, I., and Massague, J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
46. Luo, Y., Hurwitz, J., and Massague, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (Lond.), 375: 159-161, 1995.